TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22052885

Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and 5-FC (25 mg/kg 4 times daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and fluconazole (800 mg daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and fluconazole (600 mg twice daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and voriconazole (300 mg twice daily)
Number of subjects: 80
Study: 20193727

Group type: EXPERIMENTAL
Intervention: Poly-acid modified resin composite/resin composite sandwich restoration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Direct resin composite restoration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Laminate restoration
Number of subjects: 29
Study: 17397426

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Home Safety Assessment and Modification (HSAM)
Number of subjects: 150
Study: 15614689

Group type: EXPERIMENTAL
Intervention: Synbiotic containing Bifidobacterium bifidum BB‐02 and Bifidobacterium lactis BL‐01 with inulin-based prebiotic (Synergy 1; Orafti)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Synbiotic consumption
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Synbiotic feeding
Number of subjects: 18
Study: 11408002

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with nephropathy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients without nephropathy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with retinopathy
Number of subjects: 35
Study: 9409334

Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Naratriptan 0.25 mg
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg and 1 mg
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Naratriptan
Number of subjects: 586

Group type: COMPARATOR
Intervention: Naratriptan and placebo
Number of subjects: 586
Study: 8202976

Group type: EXPERIMENTAL
Intervention: Sensory stimulation (including electrostimulation)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (same physiotherapy and occupational therapy)
Number of subjects: 78
Study: 3308647

Group type: EXPERIMENTAL
Intervention: Internal gas tamponade without episcleral buckle
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 120
Study: 31288906

Group type: EXPERIMENTAL
Intervention: No chest tube (NCT group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Chest tube (CT group)
Number of subjects: 74
Study: 28432049

Group type: EXPERIMENTAL
Intervention: Swallowed aspirin taken simultaneously with niacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally dissolved aspirin taken simultaneously with niacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both orally dissolved and swallowed aspirin taken simultaneously with niacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25403142

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed using the Patient Health Questionnaire‐9 (PHQ‐9)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Pain assessed using the Short Form McGill Pain Questionnaire (SF‐MPQ)
Number of subjects: 286
Study: 24130254

Group type: EXPERIMENTAL
Intervention: Palliative Care Trial (PCT) recruitment protocol
Number of subjects: 461
Study: 20880286

Group type: EXPERIMENTAL
Intervention: 100 mg bee pollen/kg BW
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200 mg bee pollen/kg BW
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 300 mg bee pollen/kg BW
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (0 mg bee pollen/kg BW)
Number of subjects: 40
Study: 19660800

Group type: EXPERIMENTAL
Intervention: Zuidex (mid-urethral injection)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Contigen (proximal urethral cystoscopic injection)
Number of subjects: 344
Study: 16883093

Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Epinastine
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 685

Group type: COMPARATOR
Intervention: Non-treatment
Number of subjects: 685
Study: 14759446

Group type: EXPERIMENTAL
Intervention: HSD solution (4 mL/kg during 20 minutes before cardiopulmonary bypass)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ringer solution (same volume as HSD)
Number of subjects: 50
Study: 11726445

Group type: EXPERIMENTAL
Intervention: Propofol administered using TCI at target concentrations of 1.5-4.5 microg/mL to pregnant women.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propofol administered using TCI at target concentrations of 1.5-4.5 microg/mL to nonpregnant women.
Number of subjects: 72
Study: 9212372

Group type: EXPERIMENTAL
Intervention: Multicomponent competence enhancement intervention (MCEI)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Information/attention control (IAC)
Number of subjects: 309
Study: 8424001

Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Television viewing in obese children
Number of subjects: 31

Group type: COMPARATOR
Intervention: Resting energy expenditure
Number of subjects: 31
Study: 3664551

Group type: EXPERIMENTAL
Intervention: Shampoo (pyrethrin-piperonyl-butoxide)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lotion (pyrethrin-piperonyl-butoxide)
Number of subjects: 40
Study: 29258890

Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 27436332

Group type: EXPERIMENTAL
Intervention: Culturally tailored ANBL program
Number of subjects: 463

Group type: COMPARATOR
Intervention: Non-tailored current best practices (CBP)
Number of subjects: 463
Study: 26424673

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 484

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir 800 mg plus ritonavir 100 mg
Number of subjects: 484
Study: 22895370

Group type: EXPERIMENTAL
Intervention: 30G + MOD (30 g of glucose preexercise)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0G + MOD (0 g of glucose preexercise)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0G + MOD/INT (0 g of glucose preexercise with high-intensity intervals)
Number of subjects: 11
Study: 21718512

Group type: EXPERIMENTAL
Intervention: Website only
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Website with peer-led support
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Website with professional email-counseling
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 306
Study: 18645518

Group type: EXPERIMENTAL
Intervention: Counselor-delivered intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 152
Study: 16527680

Group type: EXPERIMENTAL
Intervention: Alternating occlusion (full time and symmetric for those with no amblyopia, asymmetric for those with amblyopia)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (occlusion for amblyopia only)
Number of subjects: 44
Study: 12872052

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (low-dose diuretic)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin-II-receptor blocker)
Number of subjects: 392
Study: 11119182

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 228
Study: 7640592

Group type: COMPARATOR
Intervention: General practitioners
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: Senior house officers
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: Registrars
Number of subjects: 1702
Study: 2508341

Group type: EXPERIMENTAL
Intervention: CO2-baths with high CO2-concentration
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: CO2-baths with low CO2-concentration
Number of subjects: 423

Group type: COMPARATOR
Intervention: CO2-baths (both high and low concentration)
Number of subjects: 423
Study: 31851795

Group type: EXPERIMENTAL
Intervention: Anifrolumab (300 mg) every 4 weeks for 48 weeks
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 31234927

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy (n=82)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy (control group; n=81)
Number of subjects: 163
Study: 27796604

Group type: EXPERIMENTAL
Intervention: Real tDCS plus occupational therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tDCS plus occupational therapy
Number of subjects: 23
Study: 25969155

Group type: EXPERIMENTAL
Intervention: 5% NaF/5% TMP varnish
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5% NaF varnish
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (no F or TMP)
Number of subjects: 12
Study: 24949710

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21723639

Group type: EXPERIMENTAL
Intervention: Divided attention training (30 min) while taking big steps and performing serial three subtractions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Divided attention training (30 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study: 19615959

Group type: EXPERIMENTAL
Intervention: Probiotic dairy drink containing Lactobacillus casei DN-114 001 and yoghurt ferments (Actimel), consumed twice daily for 7 weeks (pilot) or 13 weeks (confirmatory).
Number of subjects: 308

Group type: COMPARATOR
Intervention: Non-fermented control dairy product, consumed twice daily for 7 weeks (pilot) or 13 weeks (confirmatory).
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Probiotic dairy drink (Actimel).
Number of subjects: 308
Study: 17250579

Group type: EXPERIMENTAL
Intervention: Application of periodontal dressing to sensitive teeth
Number of subjects: 22

Group type: COMPARATOR
Intervention: No periodontal dressing (control)
Number of subjects: 22
Study: 15710008

Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 2251

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 2251
Study: 12665918

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg once a day for one year
Number of subjects: 94

Group type: COMPARATOR
Intervention: Common liver protection drugs
Number of subjects: 94
Study: 9699124

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.1 IU/Kg i.m. for 3 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pure FSH (75 IU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 18
Study: 8519676

Group type: EXPERIMENTAL
Intervention: Carboplatin + Amifostine (CA arm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Carboplatin alone (C arm)
Number of subjects: 21
Study: 1683503

Group type: EXPERIMENTAL
Intervention: Quinagolide 0.05 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quinagolide (incremental doses for 6 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bromocriptine (incremental doses for 6 months)
Number of subjects: 19
Study: 7055053

Group type: EXPERIMENTAL
Intervention: Axial 60-degree LAO view
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Axial 45-degree RAO view
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional 30-degree RAO/60-degree LAO projection
Number of subjects: 36
Study: 30218226

Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions including the use of tongue scraper
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral hygiene instructions alone without tongue cleaning
Number of subjects: 36
Study: 28945850

Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 296

Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed plus pemetrexed maintenance
Number of subjects: 296
Study: 25784519

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for 8 days starting 48 hours before surgery)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 59
Study: 22626867

Group type: EXPERIMENTAL
Intervention: Left anodal tDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subjective mood and anxiety evaluation
Number of subjects: 20
Study: 21484242

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 0
Study: 19137320

Group type: EXPERIMENTAL
Intervention: 0.1% ISMN gel
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0.1% GTN gel
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17700043

Group type: EXPERIMENTAL
Intervention: Mandibular repositioning appliance (MRA)
Number of subjects: 50
Study: 14995003

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IVCYC) 0.5 g/m² body surface area, monthly
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral enalapril 10 mg/day
Number of subjects: 34
Study: 11483846

Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 9608348

Group type: EXPERIMENTAL
Intervention: Frequent take-home medication doses during baseline (8-week duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg take-home doses during contingency management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine 0 mg and 20 mg take-home doses during contingency management
Number of subjects: 0
Study: 8107741

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (1.5 million units thrice weekly for 1 week, then 3 million units thrice weekly for 23 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no additional treatment apart from previously prescribed treatments)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (resumption of treatment)
Number of subjects: 53
Study: 2532624

Group type: EXPERIMENTAL
Intervention: Experimental dentine-enamel adhesive (ferric oxalate, N‐phenylglycine, PMDM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light-cured Scotch-bond
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZOE (Zinc Oxide Eugenol)
Number of subjects: 0
Study: 4886628

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Arvin
Number of subjects: 30
Study: 30822358

Group type: EXPERIMENTAL
Intervention: Biologic therapies (ustekinumab) in RCTs
Number of subjects: 8811

Group type: COMPARATOR
Intervention: Real-world populations on biologic therapies
Number of subjects: 8811
Study: 28686199

Group type: EXPERIMENTAL
Intervention: High GI breakfast (64.0 GI and 1318 KJ energy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low GI breakfast (29.4 GI and 1489 KJ energy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control conditions (only water)
Number of subjects: 40
Study: 26700981

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (two 200-μg tablets every 4 hours for up to 48 hours)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Vaginal misoprostol (two 200-μg tablets inserted every 4 hours for 48 hours)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Combination route (two 200-μg tablets vaginally followed by 400 μg sublingually every 4 hours for 48 hours)
Number of subjects: 195
Study: 23389691

Group type: EXPERIMENTAL
Intervention: GABAergic mechanism involvement in the ventromedial prefrontal cortex (vmPFC) during aversive-aversive stimulus interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GABAA receptors in vmPFC and sensorimotor cortex
Number of subjects: 0
Study: 21848959

Group type: EXPERIMENTAL
Intervention: 0.5 g of pure ethanol/kg of body weight (low dose: LD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 g of pure ethanol/kg of body weight (high dose: HD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0 g of pure ethanol/kg of body weight (control)
Number of subjects: 10
Study: 18089452

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 2103
Study: 16760409

Group type: EXPERIMENTAL
Intervention: CCL3 production in infants born to HIV-positive mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCL3 production in infants who acquired HIV-1 infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCL3-L1 gene copy number
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deficient CCL3 production phenotype
Number of subjects: 0
Study: 14735686

Group type: EXPERIMENTAL
Intervention: Schedule A (weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schedule B (twice weekly for 2 weeks repeated every 21 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schedule C (twice weekly every other week)
Number of subjects: 0
Study: 10872013

Group type: EXPERIMENTAL
Intervention: Monetary sanction intervention group (n=1500)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control group (n=1000)
Number of subjects: 2500
Study: 9123739

Group type: EXPERIMENTAL
Intervention: Neoadjuvant total androgen deprivation using LHRH analog (goserelin) plus flutamide for 3 months
Number of subjects: 354

Group type: COMPARATOR
Intervention: Direct radical prostatectomy
Number of subjects: 354
Study: 7901080

Group type: EXPERIMENTAL
Intervention: Carboprost trometamol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Methylergometrine
Number of subjects: 150
Study: 4025164

Group type: EXPERIMENTAL
Intervention: FDP (250 mg/kg body weight in isotonic saline solution intravenously in 20 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30954336

Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry exposure (n = 44)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry exposure
Number of subjects: 84
Study: 30108392

Group type: EXPERIMENTAL
Intervention: Melatonin 10mg orally via nasogastric tube at admission
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 80
Study: 26086689

Group type: EXPERIMENTAL
Intervention: Active awareness on physical health
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 0
Study: 23721512

Group type: EXPERIMENTAL
Intervention: Cladribine-based combinations (CMC: 2-CdA, cyclophosphamide, mitoxantrone; CC: 2-CdA, cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-CdA monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladribine-based combinations (CMC, CC)
Number of subjects: 0
Study: 21855284

Group type: EXPERIMENTAL
Intervention: Tpos1-adequate group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tpos1-inadequate group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tpos1
Number of subjects: 48
Study: 20584260

Group type: EXPERIMENTAL
Intervention: GIP 2 pmol kg(‐1) min(‐1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GIP 5 pmol kg(‐1) min(‐1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GLP‐1 0.75 pmol kg(‐1) min(‐1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: NaCl (Control)
Number of subjects: 17
Study: 17354241

Group type: EXPERIMENTAL
Intervention: hrHPV testing
Number of subjects: 2193

Group type: COMPARATOR
Intervention: Cytology testing
Number of subjects: 2193

Group type: EXPERIMENTAL
Intervention: hrHPV-positive smear
Number of subjects: 2193
Study: 15716285

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Angiotensin II blockade (losartan)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Chronic heart failure
Number of subjects: 352
Study: 12045171

Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg daily) for 28 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 9468739

Group type: EXPERIMENTAL
Intervention: Body image measures for females (NBS-Female, CBS, ABS, LTB)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Body image measures for males (NBS-Male, CBS, ABS, LTB)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Obese and very obese females
Number of subjects: 172
Study: 7710412

Group type: EXPERIMENTAL
Intervention: Myo device, chewed for four minutes, twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (customary oral hygiene procedures only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Myo device
Number of subjects: 30
Study: 2632755

Group type: COMPARATOR
Intervention: Dialysis with a 'low-calcium' dialysate (1.50 mmol/l)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dialysis with a 'high-calcium' dialysate (1.75 mmol/l)
Number of subjects: 26
Study: 29124329

Group type: EXPERIMENTAL
Intervention: Low-intensity, home-based program (Onco-Move)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Moderate- to high-intensity, combined supervised resistance and aerobic exercise program (OnTrack)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 63